Chief Development Officer
Dr. Matkovits joined Matinas as Chief Development Officer in October 2018. She brings extensive global drug development and commercialization experience with vast expertise ranging from large global multinational pharmaceutical companies to mid-size and small biotech settings and spans all phases of drug development including bringing to market a number of globally-approved and registered products and late-stage products including biologics, small molecules, and devices across multiple therapeutic areas.
Previously Dr. Matkovits served as the Chief Operating Officer of ContraVir Pharmaceuticals (now Hepion) (NASDAQ: CTRV) where she was instrumental in the establishment and build-out of its global development organization with responsibility and oversight for Clinical Development, Regulatory, Manufacturing, Quality, and Project Management functions, including the leadership of the global development efforts for the company's antiviral portfolio. Prior to that, Dr. Matkovits served as Global Program Leader at NPS Pharmaceuticals where she led the integration of two commercial assets acquired from Takeda into NPS, and led the company in the successful approval of Natpara in the U.S. During her tenure, Dr. Matkovits was a key contributor in the expansion of NPS from a U.S.-centric to a global development and commercial organization. Prior to her time at NPS, Dr. Matkovits was Vice President, Innovation Leader at the Medicines Company (NASDAQ: MDCO), where she led the successful global development and registration of oritavancin, which is now approved and commercialized in the U.S. and EU as ORBACTIV. Earlier in her career, Dr. Matkovits held a number of global leadership positions at Novartis across Global Development and the U.S. Commercial Organization, including as Head, Strategic Planning and Operations, U.S. Medical and Drug Regulatory Affairs.
Dr. Matkovits serves on the Board of Directors of BioSurplus and also serves as an Independent Director of Appili Therapeutics (APLI: TSXV). Dr. Matkovits earned her Ph.D. in Biochemistry and Molecular Biology from the University of Medicine and Dentistry of NJ.